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reverse remodeling drug because the final dose of carvedilol was
25% higher in this treatment arm. This would be expected from
previous large-scale beta-blocker trials. Any additional agent on
top of what is already working may yield a smaller incremental
effect as the investigators also demonstrated in the perindopril-
initiated arm.
What this “humble” study confirms are that beta-blockers are
important in patients with NYHA functional class II or above, that
diligence and patience must be used to up-titrate to the highest
dose tolerated, and that we should not withhold use of beta-
blockade even if a patient feels better without it. The impact of the
study is not which agent to initiate first, but that both must be used
without delay.
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Beta-Blocker Treatment Before
Angiotensin-Converting Enzyme Inhibitor
Therapy in Newly Diagnosed Heart Failure
We read with great interest the study by Sliwa et al. (1) recently
published in the Journal. In their report they observed that,
compared to the commonly recommended order of starting ther-
apy for newly diagnosed heart failure with an angiotensin-
converting enzyme inhibitor (ACEI) followed by a beta-blocker,
the opposite order of starting with the beta-blocker carvedilol
followed by the ACEI perindopril had a superior effect on New
York Heart Association (NYHA) functional class, left ventricular
ejection fraction (LVEF), plasma N-terminal pro-brain natriuretic
peptide concentration, and LV volumes. We believe that this is a
very important study and the investigators are to be congratulated
for their achievement. In his accompanying editorial (2), Dr. Leier
points out that a large multicenter morbidity/mortality trial would
have to be performed to verify the results obtained by Sliwa et al.
In response to this we would like to inform readers of JACC
that, based on a hypothesis similar to the one by Sliwa et al., we
started planning such a morbidity/mortality trial more than four
years ago. The rationale and design of this trial, the Cardiac
Insufficiency Bisoprolol Study (CIBIS)-III, has been published (3),
and the study is now concluded. In 18 European countries, as well
as in Tunisia and Australia, 1,013 patients with NYHA functional
class II to III heart failure have been included.
The CIBIS-III trial is designed to provide evidence for the best
order of initiating therapy. The end point rate is as expected,
ensuring an adequate statistical power to show noninferiority or
superiority for bisoprolol-first, should that be the case. If superi-
ority for either treatment regimen is shown we will know if we
generally should start heart failure therapy with an ACEI or a
beta-blocker. If the trial shows noninferiority for bisoprolol-first
versus enalapril-first, there is evidence supporting a free choice
with regard to the first therapy, based on individual judgment in
each patient. A result showing that bisoprolol-first is superior to
enalapril-first will challenge the paradigm of testing compounds
for the treatment of heart failure against a background of ACEI
therapy.
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Treatment Order in Managing
Systolic Ventricular Dysfunction
Dr. Leier (1) has made a useful and provocative commentary on
the work of Sliwa et al. (2). Clearly Dr. Leier is impressed by the
principle of testing order effects in the management of systolic left
ventricular (LV) dysfunction. This is a very wise and long overdue
assessment although not performed in a double-blinded random-
ized crossover design that would be expected to characterize an
order effect. It would be equally wise to retain balance in estimating
the impact or generalizability of this work.
First, it is often forgotten that all modern studies in systolic
failure involve structured addition of therapy to established treat-
ments. Although we often focus on the added therapy we tend to
ignore the baseline, which is constantly changing and makes
proving efficacy of a new addition consequently more challenging.
For example, all patients in the angiotensin-converting enzyme
(ACE) inhibitor, ino-dilator, or vasodilator and digoxin systolic
failure trials of the 1980s and 1990s were subjected to loop diuretic
therapy, which has a powerful impact in stimulating the circulating
and tissue-based (renin-angiotensin-aldosterone system). The
well-characterized and accepted adverse effects of the changes
caused by these treatments are balanced in the individual patient by
the beneficial effect on fluid volume and loading. Although
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